immune thrombocytopenia
Conditions
Interventions
Experimental group:low-dose cyclosporine A combined with EPAG
Sponsors
Zhejiang Provincial Hospital of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
12 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.Patients eligible for inclusion were: compliance with Consensus of Chinese Experts on Diagnosis and Treatment of Adult Primary ITP(version 2020) 2.18 years or older; 3.Platelet count<20×10^9/L with varying degrees of bleeding symptoms before admission; 4.Failed from multiple lines of therapy: patients are ineffective or dependent on first-line glucocorticoid therapy, no response to previous rhTPO (at least 15000U qd for 14 days), and failed from prior EPAG ongoing treatment (at least 75mg qd for 30 days).
Exclusion criteria
Exclusion criteria: 1.Key exclusion criteria were severe cardiopulmonary dysfunction, hepatic and renal insufficiency, immunodeficiency; 2.pregnant or lactating women; 3. with a history of thrombosis or autoimmune diseases. 4.Bone marrow aspiration and biopsy were performed before the administration of EPAG, the secondary thrombocytopenia including myelodysplastic syndrome (MDS), aplastic anemia (AA), thrombocytopenia (TTP), etc. were excluded based on comprehensive differentiation diagnosis.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| blood routine;efficacy;response duration;concomitant medication;bleeding symptoms;safety; | — |
Countries
China
Contacts
Public ContactWu Dijiong
the First Affiliated Hospital of Zhejiang Chinese Medical University Youdian Road NO.54 Department of Hematology Hangzhou, Zhejiang
Outcome results
None listed